Skip to main content


Almotriptan in the acute treatment of migraine in patients 11–17 years old: an open–label pilot study of efficacy and safety

Article metrics

  • 254 Accesses

  • 19 Citations


The objective was to investigate the safety and efficacy of almotriptan in patients aged 11–17 years old with acute migraine. Fifteen patients aged 11–17 with a history of migraine with or without aura were treated with almotriptan. Reduction in headache severity, disability and adverse effects were studied. Almotriptan in doses ranging from 6.25 to 12.5 mg was well tolerated. There were virtually no adverse effects except for one case of transient mild stiffness. Of the 15 patients, only 2 demonstrated no efficacy without adverse effects. In the other 13 patients, not only was almotriptan effective, but again, no significant adverse effects were reported. Almotriptan is probably safe and effective in patients aged 11–17. This small open–label pilot study should support the feasibility of a large randomised controlled study to demonstrate tolerability and efficacy of almotriptan in children and adolescents with episodic migraine.

Author information

Correspondence to J. A. Charles.

Rights and permissions

Reprints and Permissions

About this article

Key words

  • Almotriptan
  • Migraine
  • Adolescent
  • Children
  • Triptan


By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate. Please note that comments may be removed without notice if they are flagged by another user or do not comply with our community guidelines.